Matthew Martinez, MD
Cardiovascular Disease · Allentown, PANPI 1770556243
Payments from drug & device makers
Across 534 payments — averaging $1243.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$616K
- Novartis$41K
- Irhythm Technologies, Inc.$3K
- Sanofi$1K
- Pfizer$393
- Amgen$325
- plus $2K from 21 others
What the payments were for
- Consulting fees$83,27520%
- Speaking & faculty fees$284,33268%
- Travel & lodging$41,47810%
- Food & beverage$9,6322%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 353 | $616,135 |
| Novartis | 35 | $41,039 |
| Irhythm Technologies, Inc. | 4 | $3,070 |
| Sanofi | 16 | $1,241 |
| Pfizer | 27 | $393 |
| Amgen | 20 | $325 |
| Boehringer Ingelheim | 21 | $325 |
| Bristol Myers Squibb | 1 | $300 |
| AstraZeneca | 8 | $120 |
| Alnylam Pharmaceuticals Inc. | 7 | $117 |
| Medical Graphics Corporation | 1 | $95 |
| Novo Nordisk | 5 | $83 |
| Merck | 4 | $69 |
| Lexicon Pharmaceuticals, Inc. | 4 | $67 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $64 |
| Heartflow, Inc. | 3 | $61 |
| Johnson & Johnson | 3 | $52 |
| Baxter Healthcare | 2 | $51 |
| Boston Scientific | 2 | $46 |
| Bardy Diagnostics, Inc. | 4 | $44 |
| Bayer | 2 | $42 |
| Bridgebio Pharma, Inc. | 2 | $34 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Kestra Medical Technology Services, Inc. | 1 | $25 |
| Chiesi USA, Inc. | 1 | $23 |
| Amicus Therapeutics, Inc. | 1 | $23 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$14,171
- ZIO XT Patch$3,000
- Zio monitor$3,000
How this compares
$663,897 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CamzyosMavacamten | 354 | $2,869,816 |
| EliquisApixaban | 55 | $73,866 |
| JardianceEmpagliflozin | 58 | $64,427 |
| EntrestoSacubitril/Valsartan | 45 | $56,294 |
| FarxigaDapagliflozin Propanediol | 41 | $45,776 |
| Verapamil ErVerapamil Hcl | 73 | $2,578 |
| Metoprolol Succinate | 106 | $1,442 |
| Valsartan | 13 | $640 |
| Losartan Potassium | 40 | $555 |
| Spironolactone | 31 | $457 |
| Rosuvastatin Calcium | 12 | $323 |
| Atorvastatin Calcium | 28 | $241 |
| Metoprolol Tartrate | 17 | $134 |
| Amoxicillin | 65 | $61 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Camzyos | $616,135 | $2,869,816354 claims |
| PfizerEliquis | $393 | $73,86655 claims |
| Boehringer IngelheimJardiance | $325 | $64,42758 claims |
| NovartisEntresto | $41,039 | $56,29445 claims |
| AstraZenecaFarxiga | $120 | $45,77641 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Other cardiovascular disease in Allentown
- Sabahat BokhariAllentown$791K
- Danielle DuffyPhiladelphia$29.5M
- Venkatesh NadarCamp Hill$18.3M
- Hemal GadaWormleysburg$6.7M
- Brian DrachmanPhiladelphia$3.8M
- William BachinskyMechanicsburg$2.3M
- Bonnie KyPhiladelphia$1.9M
- Benjamin KalsmithPgh$1.7M
- Marielle Scherrer CrosbiePhiladelphia$1.6M
- Paul GrenaYardley$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.